Groowe Groowe / Newsroom / REGN
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

REGN News

Regeneron Pharmaceuticals Inc

Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

prnewswire.com
REGN

CIO 100 Awards & Conference Announces 2026 CIO 100 Honorees, Recognizing Enterprise-Scale Technology Leadership

accessnewswire.com
HPE IBM AVNT AX BAC MSFT BRK.A JNJ MRK AMZN GOOG QCOM T VZ MU INTC AMD NVDA CRM ADBE CSCO ORCL SAP ACN MS AXP MA V UNM ALL CB TRV GE HON MMM DOW DD EL KHC PEP KO MCD SBUX CMG YUM DG WMT TGT HD LOW COST UPS FDX XPO JBHT CNC CI ELV HCA CVS UNP NSC BNTX MRNA GILD AMGN REGN ABBV BMY PFE LLY SNY AZN ELAN MSCI FICO EXPD BKNG MAR H WYNN LVS MGM CCL RCL NCLH LULU UA NKE RL PVH TJX BBY MDT ISRG ABT BA LMT RTX GD CAT DE CNH OSK J CBRE JLL SPG PLD AMT EQIX CCI AVTR BIIB ALGN EXPE AEP NEE SO DUK PCG SRE WEC ED D ETR NI PNW EXC EIX FE CMS LNT ZION KEY PNC USB WFC JPM GS SCHW SPGI AMAT AVGO NXPI ADI TXN MRVL SNPS CDNS MCHP ON INFY WDC SE BABA JD PDD MELI ETSY EBAY SHOP PYPL COIN HOOD UPST SOFI AFRM PLTR SNOW DDOG PANW CRWD ZS FTNT CHKP CYBR TENB NTAP STX APP MOVE ACCL AES ALB APLS ASML BKR BROS BWA CHTR EOG EXAS F FCX KMB L LBRDK LUV MAS META MNST MO MTRX NOC O OC ODFL OTIS OXM PAYX PHI PPC PRGO PSX RF ROST ROKU RS S SEE SIRI TCOM THC THG THS TIGR TMO TMUS TOL TOP TRIP TRMB TRN TSLA TTWO TXRH UDR ULTA UNFI UNH VRSK VRTX VTR W WHR WMB WST WY XOM XRAY XYL YMM Z ZBH ZBRA ZTO ZTS

Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

businesswire.com
REGN

Институт Critical Path Institute запускает программу One to Millions, чтобы изменить будущее персонализированной медицины в глобальном масштабе USA - Pусский USA - English USA - English USA - Français USA - slovenčina USA - Polski USA - español USA -

prnewswire.com
BMY MRK PFE GILD REGN AZN NVS BIIB ALKS CRIS EDIT NTLA

Bispecific T-Cell Engagers Market Insights Report (2026-2030) Featuring Strategic Analysis of Pfizer, Johnson & Johnson, Roche, AbbVie, Sanofi and Other Key Players

globenewswire.com
PFE JNJ AMGN ABBV SNY REGN MRK

Pruritus Therapeutics Market Size is Projected to Reach USD 15.58 Billion by 2035 Due to the Increasing Cases of Chronic Inflammatory Skin Diseases Globally | SNS Insider

globenewswire.com
REGN LULU

Inveniam Hires Former Bloomberg and Moody's Leader to Meet Rising Institutional Demand for AI-Ready Data

prnewswire.com
IBM MUFG MS GS JPM BAC WFC SCHW AMTD AXP V MA PYPL COF SYK BMY PFE MRK JNJ UNH CVS CI AMGN GILD BIIB REGN AZN NVS TSM NVDA INTC AMD QCOM AMAT LRCX MU ADBE CRM GOOG GOOGL AMZN MSFT AAPL META NFLX CMCSA T VZ DIS HD MCD SBUX KO PEP CAT BA GE XOM CVX HSBC BCS NYT BKR HAL SLB COP EOG APA OXY DVN

Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026

globenewswire.com
REGN

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

globenewswire.com
REGN SNY

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

globenewswire.com
SNY REGN